Sarclisa SC BLA Review Extended Three Months as FDA Scrutinizes OBI Filing

Sanofi's biologics license application for Sarclisa (isatuximab-irfc) subcutaneous formulation is facing a review extension of up to three months at the FDA, pushing the revised target action date to July 23, 2026. The delay reflects the regulatory complexity inherent in combination product submissions where a novel delivery device -- in this case, an on-body injector (OBI) -- is integrated into the filing. For regulatory affairs leads and quality teams tracking oncology biologic submissions, the agency's handling of this BLA is shaping up as a reference case for how combination product dossiers will be evaluated under existing frameworks.

If approved, Sarclisa SC would represent the first anticancer treatment administered via an on-body injector, a distinction that carries significant implications beyond this single product. Combination product submissions involving novel delivery mechanisms require coordinated review across FDA centers, and the additional three months signals the agency's need for deeper technical assessment of the OBI component alongside the biologic itself. Sponsors preparing similar filings -- particularly those developing subcutaneous reformulations of established IV oncology agents -- should treat this timeline adjustment as a data point when building their own regulatory strategies and CMC packages.

The SC formulation is under review for use in combination with approved standard-of-care regimens for multiple myeloma patients across all currently approved US indications for the Sarclisa IV formulation. The European regulatory pathway has moved further along: on March 26, 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Sarclisa SC -- administered via both OBI and manual injection -- for MM patients across all currently approved EU indications and combinations. A final European Commission decision is expected within the coming months, meaning the EU approval could precede US action by a meaningful interval.

Sarclisa (isatuximab-irfc) holds approvals in nearly 60 countries across four indications covering certain patients with newly diagnosed multiple myeloma and relapsed or refractory multiple myeloma. Sarclisa-based regimens have been prescribed to more than 60,000 patients worldwide. The SC formulation, if cleared, would expand administration options for a patient population that already carries a significant treatment burden, and the OBI route could reduce chair time and healthcare resource utilization in infusion centers -- considerations that pharmacy directors and site-of-care planners will be monitoring closely as the July decision date approaches.

Source: Sanofi press release via GlobeNewswire, April 22, 2026. Pharma Now will provide further coverage as the FDA target action date approaches and any additional information requests become public.